Good morning, you're tuned in to Markets Desk.
Coca-Cola is putting its money where its domestic footprint is, with CFO John Murphy confirming the beverage giant will invest ten billion dollars in U.S. growth through twenty thirty. The company already claims eighty-five billion dollars in annual GDP contribution and nearly one million American jobs supported, making this a significant forward commitment at a time when domestic investment signals carry real political and economic weight.
Turning to pharma, Eli Lilly is taking its cardiometabolic pipeline to Europe this fall, presenting new data on retatrutide and two additional candidates at the European Association for the Study of Diabetes annual meeting in Milan. For Lilly investors, these presentations matter — retatrutide has generated considerable anticipation as a potential next-generation obesity and metabolic therapy, and fresh clinical data could meaningfully move the stock.
And in the technology space, a Reuters investigation into Meta's internal Project OT is raising pointed questions about Mark Zuckerberg's vision for an AI-native organization — one where agents absorb much of the human workload. The story lands at a delicate moment, as Meta simultaneously builds and sells the very AI infrastructure it is deploying internally, blurring the line between product strategy and corporate philosophy in ways the market will be watching closely.
That's the tape. Markets Desk, signing off the floor.
